Sign in
WithdrawnEarly phase 1

a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)

Key facts

Who runs it
HuidaGene Therapeutics Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
30 Mar 2023
Ended
8 Apr 2025
Type of study
Interventional
Treatments tested
  • HG205
Record updated
10 April 2025
Why it stopped
Huidagene stopped this program as lack of patients in China

Who can take part

Age
1 year to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Male or females between 1 and 16 years of age at the time the subject/parent/legal guardian signs the informed consent form
  • Willing to adhere to the protocol as evidenced by written informed consent or parental permission and subject assent
  • Molecular diagnosis of biallelic mutations in the OTOF gene with at least one mutation being p.Q829X through collected blood samples at screening
  • Based on auditory brainstem response (ABR), clinically diagnosed sensorineural hearing loss (SNHL) with the following hearing thresholds: severe (65 dB ≤ hearing threshold < 80 dB) or profound (80 dB ≤ hearing threshold < 95 dB) or complete (hearing threshold ≥ 95 dB) hearing loss in both ears
  • Acceptable hematology, clinical chemistry, and urine laboratory parameters

Who cannot take part

  • Presence of cochlear implants in the study ear
  • Prior participation in clinical study with an investigational drug within the past six months
  • Prior gene therapy treatments
  • Pre-existing other hearing-loss conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints or complications of surgery
  • Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter hearing function
  • Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation
  • Complicating systemic diseases or clinically significant abnormal baseline laboratory values

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.

The group in the trial

  • HG205Treatment being tested

    Method of Administration: Once Unilateral intracochlear injection/subject; The duration of the study for each subject includes a screening period, enrollment visit, treatment visit, a 26-week follow-up period, and a 5-year long-term safety follow-up after the injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multiple-cohort, Dose-finding, Investigator-initiated Trial to Evaluate the Safety, Tolerability, and Efficacy of HG205 RNA Base-Editing Therapy in Subjects With OTOF-p.Q829X Mutation-associated Hearing Loss
Record updated
10 April 2025